These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10355084)

  • 1. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
    Sourek J
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of protein OprF of Pseudomonas in bivalent vaccines.
    Hancock RE; Wong R
    Behring Inst Mitt; 1997 Feb; (98):283-90. PubMed ID: 9382752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
    Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 10. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
    Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
    Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease.
    Sorichter S; Baumann U; Baumgart A; Walterspacher S; von Specht BU
    Vaccine; 2009 May; 27(21):2755-9. PubMed ID: 19366571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa.
    Gabelsberger J; Knapp B; Bauersachs S; Enz UI; von Specht BU; Domdey H
    Behring Inst Mitt; 1997 Feb; (98):302-14. PubMed ID: 9382754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
    Baumann U; Mansouri E; von Specht BU
    Vaccine; 2004 Feb; 22(7):840-7. PubMed ID: 15040936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of experimental burn wound sepsis by postburn immunization with polyvalent Pseudomonas antigen.
    Nance FC; Hines JL; Fulton RE; Bornside GH
    Surgery; 1970 Jul; 68(1):248-53. PubMed ID: 10483476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht B; Knapp B; Hungerer K; Lücking C; Schmitt A; Domdey H
    J Biotechnol; 1996 Jan; 44(1-3):145-53. PubMed ID: 8717398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The cloning and expression of rhlR, a quorum sensing gene in Pseudomonas aeruginosa PAO1, and a study of its effect on bacterial clearance rate in mouse lung].
    Du BZ; Xie Y; Jia WX; Yang FL; Zeng W; Yang WQ; Cheng X; Chen T; Zhang ZR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Sep; 37(5):661-5. PubMed ID: 17037722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
    Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
    Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.